Compare Gilead Sciences, Inc. (GILD) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Logitech International SA — how do they compare? Gilead Sciences, Inc. trades at $133.03 (market cap $163.51B), while Logitech International SA trades at $99.71 (market cap $14.35B). The key difference: Gilead Sciences, Inc. is far larger — about 11.4× Logitech International SA's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | LOGI | |
|---|---|---|
Market Cap | $163.51B | $14.35B |
Sector | Health | Technology |
52-Week High | $155.80 | $126.69 |
52-Week Low | $108.22 | $85.84 |
Enterprise Value | $178.05B | $12.69B |
Dividend Yield | 2.49% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Logitech (LOGI) trades at $100.59, down 1.59% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a 20.81 P/E ratio and robust profitability, including a 14.69% net income margin and 32.78% ROE. Recent earnings beats and a partnership with Call of Duty: Modern Warfare 4 highlight growth momentum, while cash flow trends indicate operational strength despite a slight net outflow in 2025.
The outlook is mixed: analyst consensus targets $113.00 with 26% buy ratings, but technical resistance near $102 poses near-term challenges. Risks include competitive pressures and market volatility, though B2B and AI product expansion offers upside. The stock presents a balanced opportunity for growth-focused investors amid cautious sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
